Torsten Doenst

Strong International Hearts — Berlin 🇩🇪 36 hours of nonstop training —challenging, and incredibly effective. Huge thanks to Prof. @ToDoenst, @HrisKirov, and @TulioCaldonazo for this outstanding program, and to Prof. Cristian Heim and my teammate Nadine Emmerich for great teamwork

👵👴Frail and older adults remain underrepresented in revascularization trials. @HrisKirov presents rationale and design of CAB-AGE I Trial, with frailty as primary outcome after PCI vs CABG. Potential CAB-AGE II will target 5-yr hard clinical endpoints. @ToDoenst @ISCAScoronary

🔑 Fascinating keynote talks today at @ISCAScoronary: From a deep dive into how CABG and PCI truly differ, physiologically, pathologically, and clinically from @ToDoenst to an eye-opening look at the controversy shaping modern coronary trials @FaisalBakaeen @GianTorre610

NOBLEty and FAME to PCI not CABG: Not Based on Scientific Credentials - jtcvs.org/article/S0022-…

Please join me this Saturday at 8 AM EDT Time for another @ISCAScoronary Morning Talk about #OffPump #CABG How to learn it. Togehter with collegues and friends we will discuss how to become proficient in Off Pump. Event supported by @Medtronic youtube.com/watch?v=Uyn_Yi…

@drjohnm @HrisKirov @divaka_perera If we keep calling PCI and CABG revascularization, we will keep blurring our perception of outcomes, because we do not understand the underlying treatment mechanisms (doi.org/10.1016/j.jacc…).

No trial better explains the importance of evidence than REVIVED BCIS. It boggles my mind that it was negative @divaka_perera is correct, but try telling 99% of American cardiologists We still cath new LV dys pts TO FIND LESIONS TO REVASC despite negative trials #ESC2025

👉 Want to learn more? Join us at the International Coronary Congress (ICC), New York, December 2025. Where science meets innovation in coronary surgery!

🚑BREAKING NEWS. This is massive. 10 year PARTNER 2 data has been released by the company. No statistical analyses were performed. But I performed them and these is what happened at 10 years. @pomyers @rafasadaba @STS_CTsurgery @EACTS

15 surgeons. 5 countries. 1 mission: advancing minimally invasive cardiac surgery. A week of live cases, wetlabs & lectures at the Jena MICS Bootcamp = new skills, knowledge & network The winners? Our patients. Like 2x full-arterial, off-pump, no-touch-aorta MICS-CABG 🫀

Do you know what revascularization really means? app.medudy.com/course-priv/96…

JenaMICS Bootcamp 2025 on German Television 👍 ardmediathek.de/video/mdr-thur…

What if the best vaccine against heart attacks… is surgery? 🫀 CABG cuts MI risk by 51% — on par with approved vaccines. It doesn’t just treat — it prevents. A collateral prevention system for the heart. 🧠💉 Read more: tinyurl.com/3czstt4y

Skill and competence are far more important than friendly feelings.

UKJ | Around the world, around the woorld 🌎 – geht der „Jena Style“ unserer Herzchirurgie: Brasilien 🇧🇷, Mexiko 🇲🇽, Südafrika 🇿🇦, Chile 🇨🇱,... | Instagram instagram.com/p/DLp4nTYsq1f/

@gerchaud @HrisKirov @TulioCaldonazo @CardiocirugiaHH Germán, looking good…. not just the cap🙂

Rocking my new surgical cap a gift from Germany @TulioCaldonazo as we keep moving forward with our mini-thoracotomy AVR program @CardiocirugiaHH

Lifetime management of heart valve disease—treat it early and treat it right, first time - The Lancet thelancet.com/journals/lance…

@FaisalBakaeen @VictorDayan1 @mmamas1973 @DavidLBrownMD @pomyers @rafasadaba Yes, but here is why doi.org/10.1016/j.jacc… 🙂

@VictorDayan1 @mmamas1973 @DavidLBrownMD @pomyers @rafasadaba Yes. Here is why: doi.org/10.1016/j.xjon…

Should we revascularize asymptomatic patients with normal EF and 3VD (with proximal LAD)? Yes or no and please Provide the evidence to support your case. @mmamas1973 @DavidLBrownMD @FaisalBakaeen @pomyers @rafasadaba

@pash22 @pomyers @djc795 @FaisalBakaeen @Coronary4front @agtruesdell @JoeSabik @VictorDayan1 @RuelMarc1 @GianTorre610 @HrisKirov @RakanINazer @rahatheart1 @rafasadaba @Dr_Ma_of_PUMC @FarivarRobert @sloaneguy @JoChikweMD @DrNivAd @Shahzad77891064 @TomVargheseJr @AortaSurg @loremontesvilla The problem is not operating based on CT. That is easy. The problem is optimal decision-making for CABG because CT currently tends to overestimate CAD severity. So, no problem with Syntax >40 or so, but tricky when intermediate.

@pomyers @djc795 @FaisalBakaeen @Coronary4front @agtruesdell @JoeSabik @VictorDayan1 @RuelMarc1 @GianTorre610 @HrisKirov @RakanINazer @rahatheart1 @rafasadaba @Dr_Ma_of_PUMC @FarivarRobert @sloaneguy @JoChikweMD @DrNivAd @Shahzad77891064 @TomVargheseJr @AortaSurg @ToDoenst @loremontesvilla Yup, the n in that 2024 feasibility study by @ToDoenst was small =114 "Coronary bypass surgery guided by computed tomography in a low-risk population" academic.oup.com/eurheartj/arti…

Left Main PCI is not “ad hoc” if you have CT data (and discuss treatment options) in advance: and mid shaft disease with 4.5mm DES = equipoise to CABG…

@georgetolisjr True, but how do you explain that practically no trial comparing new therapies with the non-evidence based surgical procedures shows superiority?

It is not just Tricuspid regurgitation that we treat with no data, but most of what we do. Our guidelines are largely without any data to back them up. The most visible studies guiding practice are underpowered, industry sponsored observational studies. jclinepi.com/action/showPdf…

@drjohnm @mrjzacharias I fully agree. If you see the need to treat any valve regurgitation, shouldn’t the treatment goal be complete and durable elimination? That is the problem with current interventions and surgical treatments of functional regurg. Our treatment effect and durability must improve!

A really important editorial in JAMA regarding the next big area of low-value, potentially harmful intervention -- on tricuspid regurgitation. Every paragraph is spot on.